- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Sarah Butler and Lindsay Bealor Greenleaf of ADVI Health Discuss the 2024 Election | Asembia 2024
In interview anticipating their presentation at the 2024 Asembia meeting in Las Vegas, Sarah Butler, M.H.S., chief commercial officer for ADVI Health, a Washington, D.C., healthcare consulting firm, and Lindsay Bealor Greenleaf, J.D., vice president & head, federal and state policy, of the firm, discussed the role that healthcare might play in 2024 presidential election and the implications of the outcome.
Butler noted that healthcare has not been a priority in the campaign but add "how can healthcare not be a priority issue and the election?"
Butler and Greenleaf also discussed how the election's outcome might affect drug pricing policies.
He noted that President Joe Biden has talked about expanding the Inflation Reduction Act to include more drugs subject to CMS price negotiation faster.
Greenleaf said that "foreign freeloading" was a focus of the Trump administration, but its international pricing index and most favored nation models ran into legal challenges.
"If we have a second Trump administration this focus on foreign freeloading, it's definitely it's coming back," she said. "We'll be looking at those past models as a guide to what we think they they might attempt again," Greenleaf said.
GLP-1 Tiering Agreement Reached, Says Optum Rx President
May 3rd 2024Health plans that use Optum Rx as their pharmacy benefit manager (PBM) will be allowed to tier their coverage of GLP-1s and still receive rebates under an agreement the PBM has reached with the manufacturers, says the PBM president. Optum officials said later that the negotiations were still ongoing,
Read More
Specialty Pharmacies Drive Cost Savings in Value-Based Care | Asembia 2024
May 2nd 2024Earlier this week at the 2024 Asembia Specialty Pharmacy Summit in Las Vegas, Managed Healthcare Executive editors spoke with Bill McElnea, vice president of population health at Shields Health Solutions, about specialty pharmacies reducing costs for patients.
Read More
GLP-1s Are Flipping the Script, Says Doug Long | 2024 Asembia
May 1st 2024The growth in spending on the glucagon-like peptide 1 (GLP-1) agonists is a “mega tsunami,” said Doug Long, MBA, vice president industry relations for IQVIA. The script that specialty drugs are the main drivers of U.S. drug expenditures may need some revision.
Read More
